Trump’s Pharma “Deal”: Some Price Cuts, Lots of Theater

Every election, we hear the same old song: a bold promise to finally “take on Big Pharma.” This time, it’s Donald Trump in the spotlight, claiming he’s brokered a deal to bring down drug prices. And sure, a few prices might dip for a little while. But let’s not mistake a few targeted discounts for real, meaningful reform. This is political theater, plain and simple—not a fix for the broken system that makes medicine so expensive in the first place.

To be fair, when politicians publicly shame a drug company, they can sometimes force their hand. A manufacturer might agree to freeze a price here, offer a small cut on a well-known drug there, or expand a patient assistance program. These are PR moves, designed to generate positive headlines and take the heat off. Drug companies are masters at giving up a little bit of profit in one area to protect the massive revenue streams they have everywhere else. So yes, a few patients might get a little relief, but this isn’t changing the game.

Meanwhile, the real reasons our drug prices are sky-high remain completely untouched. This “deal” does nothing to shorten the ridiculously long monopolies that drug companies enjoy, nothing to reform the shady rebate system with middlemen, and nothing to give Medicare real power to negotiate prices on all drugs. And it certainly doesn’t stop new drugs from launching with astronomical price tags.

The truth is, our drug prices aren’t high because no one has asked nicely enough for them to be lower. They’re high because the entire system is built to reward eye-watering prices, secret kickbacks, and a lack of competition. A press conference isn’t going to change that.

Pharma executives have seen this play out a dozen times before. They know the difference between a real threat—like actual legislation with teeth—and a temporary political storm. This isn’t a real threat. Instead, it’s a win-win for everyone but the patient. The politician gets to look tough, the drug company gets to look cooperative without giving up much, and voters get the feeling that something is being done.

This keeps happening because drug pricing is the perfect issue for political grandstanding. It’s an emotional topic that makes everyone angry, but the underlying system is incredibly complicated. This makes it easy for politicians to perform symbolic actions that sound great but carefully avoid upsetting the powerful players who like things just the way they are.

Real reform would mean admitting some uncomfortable truths: that drug prices are tied to Wall Street expectations, that “innovation” is often used as a shield to avoid accountability, and that Americans are effectively subsidizing lower drug prices for the rest of the world. None of those make for a great campaign slogan.

So if history is any guide, we know how this will end. A couple of drugs will get cheaper for a bit, the headlines will fade, and prices for everything else will keep climbing. Patients will be left just as confused and angry as before.

Until we decide to fix the broken incentives at the heart of the system, these “deals” will continue to be all sizzle and no steak. Lowering drug prices isn’t impossible, but it won’t be done with a photo-op. It will happen when policymakers stop using it as a talking point and start treating it like the deeply broken system that needs to be torn down and rebuilt. And that, unfortunately, just doesn’t make for good television.

About Richard Meyer

I’m Richard Meyer — a 25 year healthcare marketing strategist and writer focused on the intersection of direct-to-consumer marketing, healthcare economics, and human behavior.I started Work of DTC Marketing because too much of the conversation around pharma and healthcare marketing is either overly promotional, overly technical, or completely disconnected from how the system actually works.Here, I write about what DTC really does, how incentives drive behavior inside healthcare organizations, why patients are often treated like revenue streams instead of people, and why “best practices” are frequently just recycled assumptions.My background spans digital marketing, public relations, and healthcare strategy, and my approach is pragmatic, skeptical of hype, and grounded in data and lived experience. I’m less interested in what sounds good in a deck and more interested in what actually changes outcomes — for companies, doctors, and especially patients.

View all posts by Richard Meyer →

Leave a Reply